Imcheck Therapeutics
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
31 Chemin Joseph Aiguier Cs 70071, Marse...Phone Number
+33 413961490Website
www.imchecktherapeutics.comRevenue
$9.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Imcheck Therapeutics
Founded in 2015 and headquartered in France, Imcheck Therapeutics designs and develops novel immunotherapeutics that target members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules with an initial focus on gamma delta (γ9δ2) T cells.Explore more
Imcheck Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imcheck Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Imcheck Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Imcheck Therapeutics is spiking on competitors!
Click to see if Imcheck Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Imcheck Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Imcheck Therapeutics launches new products
Imcheck Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Imcheck Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Imcheck Therapeutics
Recommended Actions
Find VP level buyers at Imcheck Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Imcheck Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Imcheck Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Imcheck Therapeutics.
Imcheck Therapeutics financials insights
Gather financial insights about Imcheck Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$21.8M
2020
Series B
$64M
2022
Series C
$86M
Imcheck Therapeutics Tech Stack
A closer look at the technologies used by Imcheck Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Imcheck Therapeutics News & Media
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual MeetingGoodwin Advises ImCheck Therapeutics on Acquisition by Ipsen for Up to €1 Billion
Life Sciences and M&A teams advised ImCheck Therapeutics on its €1B acquisition by Ipsen, expected Q1 2026, advancing next-gen γ9δ2 T cell immuno-oncology therapies. Read More.Ipsen expands oncology portfolio with €1B acquisition of French biotech ImCheck Therapeutics
Pharmaceutical company Ipsen has acquired ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. ImCheck was founded in 2015 based on the r...EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck's shareholders will be eligible to receive a payment of EUR 350 million and downstream payments, for a total potential consideration of up to EUR 1 billion. ImCheck Therapeutics is a private...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Imcheck Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2015 and headquartered in France, Imcheck Therapeutics designs and develops novel immunotherapeutics that target members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules with an initial focus on gamma delta (γ9δ2) T cells.... Read More
